ECMO combined with IABP for the treatment of fulminant myocarditis caused by the targeted drug entrectinib for lung adenocarcinoma: a case report
BackgroundEntrectinib, a recently approved multikinase inhibitor indicated for advanced ROS1-positive non-small cell lung cancer (NSCLC), has demonstrated significant survival benefits in metastatic disease. However, it carries risks of severe cardiotoxicity. We report the successful management of e...
Saved in:
| Main Authors: | Qi Yujuan, Ma Xiaozhong, Wu Zhenhua, Bai Yunpeng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1626318/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined mechanical circulatory support (Impella + ECMO) in cardiogenic shock caused by fulminant myocarditis
by: Michaela Zemkova, et al.
Published: (2025-02-01) -
A race against time: A case report of fulminant myocarditis leading to cardiogenic shock
by: Martin Joseph, et al.
Published: (2024-03-01) -
Clinical and pathological characteristics of immune checkpoint inhibitor-related fulminant myocarditis
by: Ryo Izumi, et al.
Published: (2024-11-01) -
Long-term left ventricular ejection function in fulminant and non-fulminant myocarditis: A multicenter study in China
by: Guangling Li, et al.
Published: (2025-08-01) -
Lactate Dehydrogenase Indicates Development From Fulminant Myocarditis to Chronic Persistent Myocarditis: A Multicenter Retrospective Cohort Study in China
by: Zhao Q, et al.
Published: (2025-03-01)